PP
SYRS

PDT Partners’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

PDT Partners’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,608
Closed -$429K – 1041
2021
Q3 		$429K Sell
9,608
-2,072
-18% -$101K 0.03% 510
2021
Q2 		$637K Sell
11,680
-3,064
-21% -$181K 0.04% 465
2021
Q1 		$1.1M Buy
14,744
+6,289
+74% +$653K 0.08% 355
2020
Q4 		$917K Buy
8,455
+343
+4% +$31.3K 0.06% 337
2020
Q3 		$717K Buy
8,112
+4,572
+129% +$519K 0.05% 369
2020
Q2 		$377K Buy
3,540
+10
+0.3% +$898 0.03% 476
2020
Q1 		$209K Sell
3,530
-330
-9% -$22.4K 0.02% 555
2019
Q4 		$267K Buy
3,860
+2,257
+141% +$137K 0.02% 571
2019
Q3 		$166K Sell
1,603
-417
-21% -$39.4K 0.01% 418
2019
Q2 		$187K Buy
+2,020
New +$141K 0.01% 371
2018
Q4 		– Sell
-5,185
Closed -$618K – 521
2018
Q3 		$618K Sell
5,185
-637
-11% -$73.9K 0.03% 346
2018
Q2 		$594K Sell
5,822
-718
-11% -$88.9K 0.02% 383
2018
Q1 		$849K Buy
6,540
+359
+6% +$39.3K 0.03% 373
2017
Q4 		$601K Buy
6,181
+1,844
+43% +$248K 0.02% 410
2017
Q3 		$638K Buy
+4,337
New +$816K 0.02% 406

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PDT Partners's SYRS Position: Q4 2021 in Review

PDT Partners sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 9,608 shares — an estimated $429K sold.

PDT Partners first reported a position in SYRS in Q3 2017 and held it in 15 quarters. The position peaked at $1.1M in Q1 2021. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

  • PDT Partners reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • PDT Partners sold 9,608 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $429K.
  • PDT Partners first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 15 quarters.
  • PDT Partners's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.1M in Q1 2021.
  • 90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on PDT Partners's 13F filing for Q4 2021, filed 14 Feb 2022.